Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • SARS: A Prospective Analysis of an Amoy Gardens Cohort

    Hong Kong investigators report that SARS is a triphasic illness, at least in patients given corticosteroids and ribavirin.
  • Full June 15, 2003 Issue in PDF

  • Human Coronaviruses Before SARS

    Human coronavirus OC43 accounted for 6% of respiratory illnesses studied in Normandy during a single season.
  • Norovirus and the Innate Immune System

    Data from a murine model indicates the innate immune system is critical to control of Norovirus infection.
  • Full June 1, 2003 Issue in PDF

  • Market Updates

    Chances for a Medicare reform bill in this session of Congress among the myriad choices circulating offices on the Hill largely boil down to reaching an agreement on the type of reform and how far the legislation goes toward giving private insurers some entrance to the system.
  • Agreements

    Boston Scientific (Natick, Massachusetts) said it has signed an agreement with MediGuide (Haifa, Israel), a privately held company, to develop and commercialize advanced imaging and navigational technologies for use in a broad range of less-invasive therapies.
  • Acquisitions

    Boston Scientific (BSX; Natick, Massachusetts) has made a second equity investment in and extended its exclusive option to acquire EndoTex Interventional Systems (Cupertino, California). In addition, Boston Sci has agreed to acquire EndoTex upon the achievement of certain regulatory milestones.
  • Report from Europe

    Higher costs to patients for prescription drugs and reductions in coverage by state health insurance are among changes to the public healthcare system identified by the German government late last month as it tries to come to grips with runaway costs in that sector.
  • Technology advances expand interventional cardiology’s scope

    CHICAGO, Illinois With the U.S. market introduction of the Cypher drug-eluting stent from the Cordis (Miami Lakes, Florida) unit of Johnson & Johnson (New Brunswick, New Jersey), interventional cardiology has entered a new era in which patient outcomes for revascularization procedures may, for the first time, become equivalent to surgery for many patients.